214 related articles for article (PubMed ID: 35296557)
1. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
Terrisse S; Goubet AG; Ueda K; Thomas AM; Quiniou V; Thelemaque C; Dunsmore G; Clave E; Gamat-Huber M; Yonekura S; Ferrere G; Rauber C; Pham HP; Fahrner JE; Pizzato E; Ly P; Fidelle M; Mazzenga M; Costa Silva CA; Armanini F; Pinto F; Asnicar F; Daillère R; Derosa L; Richard C; Blanchard P; Routy B; Culine S; Opolon P; Silvin A; Ginhoux F; Toubert A; Segata N; McNeel DG; Fizazi K; Kroemer G; Zitvogel L
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296557
[TBL] [Abstract][Full Text] [Related]
2. Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy.
Terrisse S; Zitvogel L; Kroemer G
Microb Cell; 2022 Dec; 9(12):202-206. PubMed ID: 36483309
[TBL] [Abstract][Full Text] [Related]
3. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
4. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
5. [Effects of androgen deprivation therapy for prostate cancer on gut microbiota and treatment].
Liu JY; Zhu YP; Han BM; Xia SJ
Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(2):84-88. PubMed ID: 36597735
[TBL] [Abstract][Full Text] [Related]
6. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
7. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.
Pernigoni N; Zagato E; Calcinotto A; Troiani M; Mestre RP; Calì B; Attanasio G; Troisi J; Minini M; Mosole S; Revandkar A; Pasquini E; Elia AR; Bossi D; Rinaldi A; Rescigno P; Flohr P; Hunt J; Neeb A; Buroni L; Guo C; Welti J; Ferrari M; Grioni M; Gauthier J; Gharaibeh RZ; Palmisano A; Lucchini GM; D'Antonio E; Merler S; Bolis M; Grassi F; Esposito A; Bellone M; Briganti A; Rescigno M; Theurillat JP; Jobin C; Gillessen S; de Bono J; Alimonti A
Science; 2021 Oct; 374(6564):216-224. PubMed ID: 34618582
[TBL] [Abstract][Full Text] [Related]
8. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
9. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
11. Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer.
Liu Y; Jiang H
Transl Androl Urol; 2020 Oct; 9(5):1937-1944. PubMed ID: 33209658
[TBL] [Abstract][Full Text] [Related]
12. A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy.
Li JKM; Wang LL; Wong CYP; Chiu PKF; Teoh JYC; Kwok HSW; Leung SCH; Wong SH; Tsui SKW; Ng CF
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1063-1072. PubMed ID: 33850270
[TBL] [Abstract][Full Text] [Related]
13. [Androgen deprivation therapy in advanced prostate cancer. Multicenter study.].
Valencia-Guadalajara VJ; Martínez-Cayuelas L; Sarrió-Sanz P; Sánchez-Caballero L; Polo-Hernández R; Chillón-Sempere FS; Galán-Llopis JA; Garcés-Valverde M; Tenza-Tenza JA; Costa-Martínez A; García Serrado-Paumard D; Escudero-Fontana E; Tello-Royloa C; Verdú-Verdú LP; Bravo-López DF; Pérez Seoane-Ballester H; Pacheco-Bru JJ; Ortiz-Gorraiz MÁ
Arch Esp Urol; 2020 Jul; 73(6):499-508. PubMed ID: 32633245
[TBL] [Abstract][Full Text] [Related]
14. Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data.
Elishmereni M; Kheifetz Y; Shukrun I; Bevan GH; Nandy D; McKenzie KM; Kohli M; Agur Z
Prostate; 2016 Jan; 76(1):48-57. PubMed ID: 26419619
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients.
Daisley BA; Chanyi RM; Abdur-Rashid K; Al KF; Gibbons S; Chmiel JA; Wilcox H; Reid G; Anderson A; Dewar M; Nair SM; Chin J; Burton JP
Nat Commun; 2020 Sep; 11(1):4822. PubMed ID: 32973149
[TBL] [Abstract][Full Text] [Related]
16. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
17. The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment.
Ku JY; Lee JZ; Ha HK
Korean J Urol; 2015 Oct; 56(10):689-94. PubMed ID: 26495069
[TBL] [Abstract][Full Text] [Related]
18. Targeting androgen-independent pathways: new chances for patients with prostate cancer?
Cattrini C; Zanardi E; Vallome G; Cavo A; Cerbone L; Di Meglio A; Fabbroni C; Latocca MM; Rizzo F; Messina C; Rubagotti A; Barboro P; Boccardo F
Crit Rev Oncol Hematol; 2017 Oct; 118():42-53. PubMed ID: 28917268
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
[TBL] [Abstract][Full Text] [Related]
20. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nishizawa K; Hattahara K; Onishi H; Yoshida T
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
